Research programme: GPR119 protein agonists - Metabolex

Drug Profile

Research programme: GPR119 protein agonists - Metabolex

Latest Information Update: 20 Dec 2013

Price : $50

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2013 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 28 Apr 2011 GPR119 protein agonists are no longer licensed to sanofi-aventis worldwide
  • 28 Jun 2010 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top